Jennifer L Clarke

Summary

Affiliation: University of California
Country: USA

Publications

  1. doi request reprint Bevacizumab and other targeted agents in the upfront treatment of glioblastoma
    Jennifer L Clarke
    Department of Neurology, University of California, San Francisco, CA Department of Neurological Surgery, University of California, San Francisco, CA Electronic address
    Semin Radiat Oncol 24:273-8. 2014
  2. doi request reprint Leptomeningeal metastasis from systemic cancer
    Jennifer L Clarke
    University of California, San Francisco, 400 Parnassus Avenue, A 808, Box 0372, San Francisco, CA 94143, USA
    Continuum (Minneap Minn) 18:328-42. 2012
  3. doi request reprint Neuroimaging: diagnosis and response assessment in glioblastoma
    Jennifer L Clarke
    Department of Neurological Surgery, Division of Neuro Oncology, University of California San Francisco, San Francisco, CA 94143 0372, USA
    Cancer J 18:26-31. 2012
  4. ncbi request reprint Pseudoprogression and pseudoresponse: challenges in brain tumor imaging
    Jennifer L Clarke
    Department of Neurological Surgery, Division of Neuro Oncology, University of California San Francisco, 400 Parnassus Avenue, A 808, Box 0372, San Francisco, CA 94143, USA
    Curr Neurol Neurosci Rep 9:241-6. 2009
  5. pmc Is surgery at progression a prognostic marker for improved 6-month progression-free survival or overall survival for patients with recurrent glioblastoma?
    Jennifer L Clarke
    Department of Neurological Surgery, University of California, San Francisco, 400 Parnassus Avenue, A 808, San Francisco, CA 94143 0372, USA
    Neuro Oncol 13:1118-24. 2011
  6. doi request reprint Recent advances in therapy for glioblastoma
    Jennifer Clarke
    Division of Neuro Oncology, Department of Neurological Surgery, University of California, San Francisco, 400 Parnassus Ave, Room A 808, Box 0372, San Francisco, CA 94143 0372, USA
    Arch Neurol 67:279-83. 2010
  7. pmc Impact of Timing of Concurrent Chemoradiation for Newly Diagnosed Glioblastoma: A Critical Review of Current Evidence
    Seunggu J Han
    Department of Neurological Surgery, Department of Epidemiology and Biostatistics, and Department of Neurology, University of California, San Francisco, San Francisco, California
    Neurosurgery 62:160-5. 2015
  8. pmc Six-month progression-free survival as an alternative primary efficacy endpoint to overall survival in newly diagnosed glioblastoma patients receiving temozolomide
    Mei Yin C Polley
    Brain Tumor Research Center, Department of Neurological Surgery, University of California San Francisco, 400 Parnassus Avenue, Room A 808, Box 0372, San Francisco, California 94143 2167, USA
    Neuro Oncol 12:274-82. 2010
  9. doi request reprint Neurosurgical management and prognosis of patients with glioblastoma that progresses during bevacizumab treatment
    Aaron J Clark
    Department of Neurological Surgery, University of California, San Francisco, San Francisco, California 94143 0112, USA
    Neurosurgery 70:361-70. 2012
  10. pmc Phase II trial of 7 days on/7 days off temozolmide for recurrent high-grade glioma
    Seunggu J Han
    Department of Neurological Surgery, University of California, San Francisco, California S J H, J D R, A M M, J L C, M D P, S M C, M S B, A D, N A B Department of Epidemiology and Biostatistics, University of California, San Francisco, California A M M
    Neuro Oncol 16:1255-62. 2014

Detail Information

Publications18

  1. doi request reprint Bevacizumab and other targeted agents in the upfront treatment of glioblastoma
    Jennifer L Clarke
    Department of Neurology, University of California, San Francisco, CA Department of Neurological Surgery, University of California, San Francisco, CA Electronic address
    Semin Radiat Oncol 24:273-8. 2014
    ..Results of recent studies of such agents are discussed. Although many of these agents show promise, none as yet has established a new standard of care for these difficult-to-treat tumors. ..
  2. doi request reprint Leptomeningeal metastasis from systemic cancer
    Jennifer L Clarke
    University of California, San Francisco, 400 Parnassus Avenue, A 808, Box 0372, San Francisco, CA 94143, USA
    Continuum (Minneap Minn) 18:328-42. 2012
    ..Leptomeningeal metastasis (LM) is an uncommon, usually late, complication of cancer. This article discusses the clinical presentation, diagnosis, prognosis, and treatment of LM...
  3. doi request reprint Neuroimaging: diagnosis and response assessment in glioblastoma
    Jennifer L Clarke
    Department of Neurological Surgery, Division of Neuro Oncology, University of California San Francisco, San Francisco, CA 94143 0372, USA
    Cancer J 18:26-31. 2012
    ....
  4. ncbi request reprint Pseudoprogression and pseudoresponse: challenges in brain tumor imaging
    Jennifer L Clarke
    Department of Neurological Surgery, Division of Neuro Oncology, University of California San Francisco, 400 Parnassus Avenue, A 808, Box 0372, San Francisco, CA 94143, USA
    Curr Neurol Neurosci Rep 9:241-6. 2009
    ..This article reviews the challenges of brain tumor imaging and its use in assessment of treatment response...
  5. pmc Is surgery at progression a prognostic marker for improved 6-month progression-free survival or overall survival for patients with recurrent glioblastoma?
    Jennifer L Clarke
    Department of Neurological Surgery, University of California, San Francisco, 400 Parnassus Avenue, A 808, San Francisco, CA 94143 0372, USA
    Neuro Oncol 13:1118-24. 2011
    ....
  6. doi request reprint Recent advances in therapy for glioblastoma
    Jennifer Clarke
    Division of Neuro Oncology, Department of Neurological Surgery, University of California, San Francisco, 400 Parnassus Ave, Room A 808, Box 0372, San Francisco, CA 94143 0372, USA
    Arch Neurol 67:279-83. 2010
    ....
  7. pmc Impact of Timing of Concurrent Chemoradiation for Newly Diagnosed Glioblastoma: A Critical Review of Current Evidence
    Seunggu J Han
    Department of Neurological Surgery, Department of Epidemiology and Biostatistics, and Department of Neurology, University of California, San Francisco, San Francisco, California
    Neurosurgery 62:160-5. 2015
    ..EORTC/NCIC, European Organisation for Research and Treatment of Cancer/National Cancer Institute of CanadaGBM, glioblastomaOS, overall survivalPFS, progression-free survivalSEER, Surveillance, Epidemiology, and End ResultsTMZ, temozolomide...
  8. pmc Six-month progression-free survival as an alternative primary efficacy endpoint to overall survival in newly diagnosed glioblastoma patients receiving temozolomide
    Mei Yin C Polley
    Brain Tumor Research Center, Department of Neurological Surgery, University of California San Francisco, 400 Parnassus Avenue, Room A 808, Box 0372, San Francisco, California 94143 2167, USA
    Neuro Oncol 12:274-82. 2010
    ..Our analysis suggests that 6-month PFS may be an appropriate primary endpoint in the context of phase II upfront GBM trials in the TMZ era...
  9. doi request reprint Neurosurgical management and prognosis of patients with glioblastoma that progresses during bevacizumab treatment
    Aaron J Clark
    Department of Neurological Surgery, University of California, San Francisco, San Francisco, California 94143 0112, USA
    Neurosurgery 70:361-70. 2012
    ..The management and prognosis of glioblastoma patients after Stupp protocol treatment and progression during bevacizumab (BV) treatment remain undefined...
  10. pmc Phase II trial of 7 days on/7 days off temozolmide for recurrent high-grade glioma
    Seunggu J Han
    Department of Neurological Surgery, University of California, San Francisco, California S J H, J D R, A M M, J L C, M D P, S M C, M S B, A D, N A B Department of Epidemiology and Biostatistics, University of California, San Francisco, California A M M
    Neuro Oncol 16:1255-62. 2014
    ..A phase II trial was performed to evaluate the efficacy of a dose-dense, 7 days on/7 days off schedule of temozolomide for patients with recurrent high-grade gliomas (HGG)...
  11. pmc Relationship of glioblastoma multiforme to the subventricular zone is associated with survival
    Nazia F Jafri
    Department of Radiology, University of California, San Francisco, San Francisco, California, USA
    Neuro Oncol 15:91-6. 2013
    ..003). Patients with GBM involving the SVZ have decreased overall survival and PFS, which may have prognostic and therapeutic implications...
  12. doi request reprint Leptomeningeal metastasis from non-small cell lung cancer: survival and the impact of whole brain radiotherapy
    Patrick G Morris
    Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    J Thorac Oncol 7:382-5. 2012
    ..A retrospective review was carried out to assess the impact of whole brain radiotherapy (WBRT), intrathecal therapy (IT), and epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) on outcomes...
  13. doi request reprint Familial gliomas: cases in two pairs of brothers
    Joseph A Osorio
    Department of Neurological Surgery, University of California, San Francisco, 505 Parnassus Ave, Rm M779, San Francisco, CA, 94143 0112, USA
    J Neurooncol 121:135-40. 2015
    ..Further investigation should focus on identifying the potential genetic links involved with cases such as the ones presented here. ..
  14. pmc Randomized phase II trial of chemoradiotherapy followed by either dose-dense or metronomic temozolomide for newly diagnosed glioblastoma
    Jennifer L Clarke
    Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY10065, USA
    J Clin Oncol 27:3861-7. 2009
    ..The goal of this randomized phase II study was to evaluate two different temozolomide regimens in the adjuvant treatment of newly diagnosed GBM...
  15. pmc Histopathologic review of pineal parenchymal tumors identifies novel morphologic subtypes and prognostic factors for outcome
    David R Raleigh
    Department of Radiation Oncology, University of California San Francisco, San Francisco, California D R R, S A L, A L, M A G, P K S, D A H K Division of Neuropathology, Department of Pathology, University of California San Francisco, San Francisco, California D A S, T T Department of Neurology, University of California San Francisco, San Francisco, California J L C Department of Neurologic Surgery, University of California San Francisco, San Francisco, California J L C, M W M, M S B
    Neuro Oncol . 2016
    ..The purpose of this study was to define the clinical behavior of PPT according to current histopathologic criteria and identify prognostic factors to guide therapeutic decisions...
  16. ncbi request reprint Chemotherapy for adult low-grade gliomas: clinical outcomes by molecular subtype in a phase II study of adjuvant temozolomide
    Michael Wahl
    Department of Radiation Oncology, University of California, San Francisco M W Department of Pathology, University of California, San Francisco J J P, A P Department of Neurosurgery, University of California, San Francisco J J P, A M M, Y L, A P, J F C, N B, J L C, M P, M S B, S M C Department of Epidemiology and Biostatistics, University of California, San Francisco A M M Department of Neurosurgery, First Affiliated Hospital of China Medical University Y L Department of Radiation Oncology, Dana Farber Cancer Institute Brigham and Women s Hospital and Harvard Medical School D D H K Department of Radiology and Biomedical Imaging, University of California, San Francisco M D, S N Department of Neurology, University of California, San Francisco J L C, S N Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco s n
    Neuro Oncol . 2016
    ..Recently described tumor classification based on molecular subtype has the potential to individualize adjuvant therapy but has not yet been evaluated as part of a prospective trial...
  17. pmc "Pulsatile" high-dose weekly erlotinib for CNS metastases from EGFR mutant non-small cell lung cancer
    Christian Grommes
    Department of Neurology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
    Neuro Oncol 13:1364-9. 2011
    ..Pulsatile erlotinib can control CNS metastases from EGFR mutant lung cancer after failure of standard daily dosing. CNS disease may not harbor acquired resistance mutations that develop systemically. A prospective trial is planned...
  18. doi request reprint Neoplastic myelopathy
    Seema Nagpal
    Division of Neuro Oncology, Department of Neurology, Stanford University, Stanford, California, USA
    Semin Neurol 32:137-45. 2012
    ..In complex cases, referral to a specialty center with access to neurosurgeons, neuroradiologists, neuropathologists, and neurooncologists is recommended...